mepsevii
ultragenyx germany gmbh - vestronidase alfa - mucopolysaccharidosis vii - fermentai - mepsevii fluorouracilu ir folino ne neurologiniai požymiai mucopolysaccharidosis vii (mps vii; sly sindromas).
zabdeno
janssen-cilag international n.v. - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemoraginės karštligės, ebola - vakcinos - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.
mvabea
janssen-cilag international n.v. - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemoraginės karštligės, ebola - vakcinos - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.
nyxthracis (previously obiltoxaximab sfl)
sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imuninės serumai ir imunoglobulinai, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.
lumoxiti
astrazeneca ab - moxetumomab pasudotox - leukemija, plaukuotoji ląstelė - antinavikiniai vaistai - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).
bylvay
albireo - odevixibat - cholestasis, intrahepatic - tulžies ir kepenų terapija - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 ir 5.
tecovirimat siga
siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - antivirusiniai vaistai sisteminiam naudojimui - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 ir 5. tecovirimat siga should be used in accordance with official recommendations.
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - amino rūgšties metabolizmas, įgimtos klaidos - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.
ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
porcilis pcv id
intervet international b.v. - kiaulių cirkoviruso tipo 2 orf2 subvieneto antigenas - immunologicals for suidae, inactivated viral vaccines - kiaulės - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection. to reduce loss of daily weight gain and mortality associated with pcv2 infection.